Jardiance fails to deliver in EMPERIAL trials for heart failure
The trial failure places doubt on the success of Jardiance in further trials for HF-REF and HF-PEF and may impact the uptake of the drug.
Akebia’s vadadustat finds uphill challenge to get safety label sans black box warning
Akebia Therapeutics’ vadadustat may have difficulty avoiding a boxed warning.
UConn selects Medable platform to study adverse digital trial events
The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare has selected digital trials platform provider Medable’s Cloud-based platform to study statin-related adverse events.
Amgen therapy improves diastolic function in heart failure with reduced ejection fraction
The COSMIC-HF trial looked at the effects of omecamtiv mecarbil in patients with stable but symptomatic heart failure.
Boehringer Ingleheim’s Jardiance set to compete as a new therapy for heart failure
Boehringer Ingelheim and Eli Lilly post their trial results at the American Heart Association Scientific Sessions 2019.
DAPA-HF blazing a trail for sodium-glucose co-transporter-2 inhibitors in heart failure
Phase III trial looked at the outcomes of AstraZeneca’s Farxiga use in patients with heart failure with reduced ejection fraction, in patients both with and without diabetes.
Merck says vericiguat’s VICTORIA trial met primary endpoint
Merck has reported that the Phase III VICTORIA clinical trial of vericiguat met its primary efficacy endpoint in patients suffering from worsening chronic heart failure with reduced ejection fraction (HFrEF).